Overview

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to ascertain the pharmacokinetics (PK) and pharmacodynamics (PD) bioequivalence of a subcutaneous (SC) injection of 1 mg (1 IU) of Glucagon (Fresenius Kabi USA) in comparison to the reference product, GlucaGen® (Bedford Laboratories), 1 mg (1 IU), SC in healthy adult subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Fresenius Kabi USA, LLC

Treatments:

Glucagon
Glucagon-Like Peptide 1